These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 27907058)

  • 1. Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk.
    Schaefer B; Würtinger P; Finkenstedt A; Braithwaite V; Viveiros A; Effenberger M; Sulzbacher I; Moschen A; Griesmacher A; Tilg H; Vogel W; Zoller H
    PLoS One; 2016; 11(12):e0167146. PubMed ID: 27907058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
    JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia.
    Cococcioni L; Pensabene L; El-Khouly S; Chadokufa S; McCartney S; Saliakellis E; Kiparissi F; Borrelli O
    Dig Liver Dis; 2021 Jul; 53(7):830-834. PubMed ID: 33775573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis.
    Schaefer B; Tobiasch M; Viveiros A; Tilg H; Kennedy NA; Wolf M; Zoller H
    Br J Clin Pharmacol; 2021 May; 87(5):2256-2273. PubMed ID: 33188534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
    Pollock RF; Muduma G
    Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions.
    Bager P; Hvas CL; Dahlerup JF
    Br J Clin Pharmacol; 2017 May; 83(5):1118-1125. PubMed ID: 27859495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypophosphatemia Is Common After Intravenous Ferric Carboxymaltose Infusion Among Patients With Symptomatic Heart Failure With Reduced Ejection Fraction.
    Dashwood A; Vale C; Laher S; Chui F; Hay K; Wong YW
    J Clin Pharmacol; 2021 Apr; 61(4):515-521. PubMed ID: 33051909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study.
    Emrich IE; Lizzi F; Siegel JD; Seiler-Mussler S; Ukena C; Kaddu-Mulindwa D; D'Amelio R; Wagenpfeil S; Brandenburg VM; Böhm M; Fliser D; Heine GH
    BMC Med; 2020 Jul; 18(1):178. PubMed ID: 32654663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
    Pollock RF; Muduma G
    J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
    [No Abstract]   [Full Text] [Related]  

  • 11. [Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia. A common side effect].
    Sánchez González R; Ternavasio-de la Vega HG; Moralejo Alonso L; Inés Revuelta S; Fuertes Martín A
    Med Clin (Barc); 2015 Aug; 145(3):108-11. PubMed ID: 25579771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.
    Pollock RF; Muduma G
    Expert Rev Hematol; 2019 Feb; 12(2):129-136. PubMed ID: 30689458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypophosphataemia after ferric carboxymaltose is unrelated to symptoms, intestinal inflammation or vitamin D status.
    Fang W; Kenny R; Rizvi QU; McMahon LP; Garg M
    BMC Gastroenterol; 2020 Jun; 20(1):183. PubMed ID: 32522150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective cohort study comparing the adverse reactions and efficacy of intravenous iron polymaltose with ferric carboxymaltose for iron deficiency anemia.
    Gilmartin CE; Hoang T; Cutts BA; Leung L
    Int J Gynaecol Obstet; 2018 Jun; 141(3):315-320. PubMed ID: 29498039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose.
    Schaefer B; Zoller H; Wolf M
    J Clin Endocrinol Metab; 2022 Mar; 107(4):1009-1019. PubMed ID: 34850000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer
    Mulder MB; van den Hoek HL; Birnie E; van Tilburg AJP; Westerman EM
    Br J Clin Pharmacol; 2019 Feb; 85(2):385-392. PubMed ID: 30393904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration.
    Klein K; Asaad S; Econs M; Rubin JE
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29298794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case report: A rare cause of severe hypophosphatemia.
    Román-Gimeno S; Ortez-Toro JJ; Peteiro-Miranda CM; Sanz-Martín B; Urdaniz-Borque R
    Ann Endocrinol (Paris); 2020 Jun; 81(2-3):125-126. PubMed ID: 32409006
    [No Abstract]   [Full Text] [Related]  

  • 20. High Risk of Hypophosphatemia in Patients with Previous Bariatric Surgery Receiving Ferric Carboxymaltose: A Prospective Cohort Study.
    Schoeb M; Räss A; Frei N; Aczél S; Brändle M; Bilz S
    Obes Surg; 2020 Jul; 30(7):2659-2666. PubMed ID: 32221822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.